2017

英文原著

  1. 1.Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K, Yamaguchi K, Yagi S, Fukuda D, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Muguruma N, Takayama T, Kishimoto I, Kangawa K, Sata M. Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoSOne 2017;12(6):e0178607. pubmed
  2. 2.Maimaituxun G, Shimabukuro M, Salim HM, Tabata M, Yuji D, Morimoto Y, Akasaka T, Matsuura T, Yagi S, Fukuda D, Yamada H, Soeki T, Sugimoto T, Tanaka M, Takanashi S, Sata M. Gender-linked impact of epicardial adipose tissue volume in patients who underwent coronary artery bypass graft surgery or non-coronary valve surgery. PLoSOne 2017;12(6):e0177170. pubmed
  3. 3.Nishio S, Kusunose K, Yamada H, Hirata Y, Ise T, Yamaguchi K, Yagi S, Soeki T, Wakatsuki T, Shimabukuro M, Sata M. Echocardiographic Epicardial Adipose Tissue Thickness Is Associated with Symptomatic Coronary Vasospasm during Provocative Testing. J Am Soc Echocardiogr 2017;30(10):1021-1027.e1. pubmed
  4. 4.Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. Vasc Pharmacol 2017;96-98:19-25. pubmed
  5. 5.Shimabukuro M, Tanaka A, Sata M, Dai K, Shibata Y, Inoue Y, Ikenaga S, Kishimoto S, Ogasawara K, Takashima A, Niki T, Arasaki O, Oshiro K, Mori Y, Ishihara M, Node K. α-glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study. Cardiovasc Diabetol 2017;12:e0177170. pubmed
  6. 6.Takagawa Y, Yagi S, Ise T, Ishii A, Nishikawa K, Fukuda D, Kusunose K, Matsuura T, Tobiume T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Katoh S, Aihara KI, Akaike M, Sata M. Improved Exercise Capacity After Cardiac Rehabilitation Is Associated with Reduced Visceral Fat in Patients with Chronic Heart Failure. Int Heart J 2017;58(5):746-51. pubmed
  7. 7.Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol 2017;16(1):48. pubmed
  8. 8.Yagi S, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D, Salim H, Maimaituxun G, Mama S, Nishio S, Takagawa Y, Tobiume T, Soeki T, Wakatsuki T, Aihara K, Akaike M, Shimabukuro M, Sata M. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2017 9;78. pubmed
  9. 9.Yagi S, Soeki T, Aihara K, Fukuda D, Ise T, Bando S, Matsuura T, Tobiume T, Yamaguchi K, Kusunose K, Yamada H, Wakatsuki T, Shimabukuro M, Akaike M, Sata M. Reduced serum level of eicosapentaenoic acid is a risk factor for cardiogenic syncope in patients with Brugada-type electrocardiogram. Int Heart J 2017:58;720-723. pubmed

英文総説

  1. 1.1. Shimabukuro M. Adiponectin and T-cadherin: a tree for biomarkers in ST-elevation or non-ST-elevation myocardial infarction. J Atheroscler Thromb 2017 in press pubmed
  2. 2.2. Shimabukuro M. Leptin resistance and lipolysis of white adipose tissue: an implication to ectopic fat disposition and its consequences. J Atheroscler Thromb in press pubmed
  3. 3.3. Yagi S, Fukuda D, Aihara K, Akaike M, Shimabukuro M, Sata M. n-3 polyunsaturated fattyacids: promising nutrients for preventing cardiovascular disease. J Atheroscler Thromb in press pubmed

英文症例

  1. 1.Hirai H, Kanno M, Watanabe T, Satoh H. Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report. Exp Ther Med 2017;14(2):1235-1240. pubmed

和文著書

  1. 1.待井典剛, 島袋充生. 糖尿病治療薬の循環器疾患関連エビデンス:ビグアナイド薬. In: 檜垣實男, 綿田裕孝, 大石充, editors. 糖尿病と循環器病 一歩進んだ糖尿病循環器学 -Diabetic Cardiology: 医薬ジャーナル社; 2017

和文総説

  1. 1.工藤明宏, 島袋充生. 高血糖が脳・心臓に与える影響. 糖尿病ケア 2017; 14(2): 125-127.
  2. 2.島袋充生.【糖尿病診療:求められる一次予防・二次予防の近未来図】Cardio-Diabetesの現在と近未来図 月刊糖尿病 2017; 9(2): 73-84.
  3. 3.益崎裕章, 島袋充生. 肥満症とメタボリックシンドローム:最近の知見と展望 日本内科学会誌 2017; 106(3): 477-83.

国際学会

The 8th Congress of the International Society for Gender Medicine 2017, Sendai, Japan, September 14 - 16, 2017

American Heart Association Scientific Sessions 2017, Anaheim, USA, November 11-15, 2017

International Diabetes Federation 2017 Congress, Abu Dhabi, UAE, 4-8 December, 2017

国内学会

第90回日本内分泌学会学術総会(京都:2017年4月20日-22日)

第60回日本糖尿病学会年次学術集会(名古屋:2017年5月18日-20日)

・益崎裕章, 島袋充生:【教育講演】肥満症 治療と病態解明における最近の進歩

国際心血管薬物療法学会日本部会 J-ISCP (東京:2017年6月17日)

第211回日本内科学会東北地方会(仙台:2017年6月17日)

第38回日本肥満学会学術総会(大阪:2017年10月7日-8日)

第55回日本糖尿病学会東北地方会(仙台:2017年11月11日)

ページの先頭へ戻る